Discovering drugs with Deep Physics and AI
 
What we do

Aqemia is an in silico drug discovery start-up, whose ambition is to discover rapidly more innovative therapeutic molecules with better chances of success.

Our science

How? Just like an AI can learn to play chess, Aqemia’s generative AI learns to invent relevant compounds thanks to unique Statistical Mechanics algorithms predicting drug-target affinity among other properties.


Aqemia's differentiation lies in its affinity prediction both accurate and 10 000x faster than competition, enabling us to guide efficiently our generative AI towards compounds with better chances to become drugs. 


Aqemia is a spin-off of the École Normale Supérieure Paris leveraging disruptive algorithms from 8 years of research. Aqemia’s team is composed of a dozen of high profiles at the crossroads of Medicinal Chemistry, Statistical Mechanics and Artificial Intelligence.

 
Founders
 

We are a mix of Science and Business, and we love solving difficult problems on topics that matter.

Maximilien Levesque
CEO 
Emmanuelle Martiano
COO

I have worked as a Researcher for the past 9 years at ENS, CEA Saclay, Cambridge, Oxford, CNRS.

I specialize in statistical mechanics and artificial intelligence. I developed Aqemia core technology with my research team.

I love science, gifs and complicated stories made simple.

I have worked as a strategy consultant at BCG in the past 9 years.

I designed and executed projects with my teams for Pharma and B2B software company leaders.

I love discovering new topics and people, diving and bringing impact through science.

Want to know more about Aqemia?

© 2020 Aqemia

  • Black LinkedIn Icon

Agoranov, 96 bis Bd Raspail, 75006 Paris